Driehaus Capital JBIO Position
Active7-Fund ConvergenceDriehaus Capital trimmed their position in Jade Biosciences, Inc. (JBIO) in Q4 2025, holding $13.7M worth of shares across 887,179 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
JBIO is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Full company profile →Driehaus Capital JBIO Position History
Frequently Asked Questions
Does Driehaus Capital own JBIO?
Yes. As of Q4 2025, Driehaus Capital holds 887,179 shares of Jade Biosciences, Inc. (JBIO) valued at $13.7M. This data comes from their SEC 13F filing.
How many hedge funds own JBIO?
7 specialist biotech hedge funds currently hold JBIO, including RA Capital Management, Baker Bros. Advisors, Deep Track Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy JBIO?
Driehaus Capital's position in JBIO was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's JBIO position increasing or decreasing?
Driehaus Capital trimmed their JBIO position in the most recent quarter, reducing by 368,619 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
JBIOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →